MolecuLight Featured in 11 Presentations and Posters at European Wound Management Association (EWMA) 2024 Annual Conference

"We are humbled by the widespread adoption of MolecuLight point-of-care devices among clinicians worldwide who see it as an invaluable and transformative tool in their wound care practices", says Anil Amlani, MolecuLight's CEO. "The impressive collection of at least 11 talks and posters from multiple and diverse facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in this specialty. The diverse array of presenters from North America, Europe, and South America underscores the global reach of the MolecuLight imaging technology. The clinical evidence showing at EWMA is echoed in the 80+ peer-reviewed publications which span the globe, showing the significant benefit of the MolecuLight i:X® and DX™ to clinical wound assessment, practice, and outcomes."

Dr. Jonathan Johnson, a wound care thought leader and health equity expert based in Washington, DC, will speak at EWMA on how MolecuLight's groundbreaking technology overcomes disparities in wound assessment on dark skin tones. "It's critical to spotlight the healthcare obstacles disproportionately impacting minority populations," he says, "and EWMA provides the perfect forum to reach a global audience with this vital work." When asked about his upcoming presentation, Dr. Johnson shares, "I'm honored to share my latest research showing how MolecuLight enhances bacterial detection in wounds regardless of skin tone, a critical limitation of traditional clinical assessment. This technology is helping break down significant barriers to equitable care. By supporting the adoption of MolecuLight imaging, we are paving the way for a healthier, fairer future."

"As the lead author of two studies to be presented at this iteration of EWMA featuring MolecuLight, I am thrilled to showcase how fluorescence signals can revolutionize bacterial management, ultimately leading to optimized wound outcomes", says Rosemarie Derwin, an experienced nurse, educator, and researcher from Dublin, Ireland, "Our research underscores how essential adequate and objective bacterial removal from the wound bed is in our efforts to achieve healing, and ultimately improve our patients' quality of life", she concludes.

The collection of 4 presentations and 7 posters featuring the MolecuLight imaging devices show how clinical decision-making is informed and enhanced through its digital wound measurement feature, detection of high bacterial burden in wounds at the bedside, and, remarkably, its ability to monitor and track wound size and bioburden over time while minimizing operator bias. Presented studies span the wound care continuum, including:

The findings that will be presented illustrate the significant clinical improvements to multiple aspects of wound care provided by the MolecuLight platform.

A selection of the clinical posters and presentation featuring the MolecuLight i:X and DX from European Wound Management Association (EWMA) 2024 Annual Conference are as follows:

(a)  Select Clinical Presentations and Workshops citing the MolecuLight point-of-care devices include:

(b)   Select Clinical Posters citing the MolecuLight point-of-care devices include:

The MolecuLight i:X and DX are the only imaging devices for the real-time detection of elevated bacterial burden in wounds that are class II FDA-cleared, CE-Marked and approved by Health Canada. With clinical evidence including over 80 peer-reviewed publications, the devices are used by leading wound care facilities globally.

MolecuLight Inc.is a privately owned medical imaging company with global presence that offers fully commercialized point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging platform technology. MolecuLight's suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging and digital wounds measurement systems and their accessories, have scientifically proven capabilities that enhance wound care practices and outcomes across all places of service. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform "fluorescence imaging for bacterial presence location, and load" and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. 

CONTACT:  Laura Jones-Donaldson, MolecuLight Inc., [email protected], T. +1.416.542.5507, www.moleculight.com

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-featured-in-11-presentations-and-posters-at-european-wound-management-association-ewma-2024-annual-conference-302130744.html